DigestRedComo funciona
Red
/
Empresas
Re
No verificado

Response Pharmaceuticals, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaFitnessIndustriaSalud

4 Comunicados de prensa

Ver todos los comunicados de prensa
05/03/2026
Industria
Biotecnología
Farmacéutica
Sanidad
Material médico sanitario
Salud
Fitness
Response Pharmaceuticals Reports Positive 36-Week Phase 2 Data Supporting RDX-002 as a Long-Term Option in Post-GLP-1 Receptor Agonist Weight Management
Fuente
Response Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
13/08/2025
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Fitness
Medicina - Varios
Industria
Response Pharmaceuticals Announces Positive Top-Line Results From Phase 2 Study of RDX-002 in Post-GLP-1 Management
Fuente
Response Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
06/02/2025
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
Response Pharmaceuticals Announces Early Completion of Enrollment of a Phase 2 Study Evaluating RDX-002 Treating Patients Discontinuing GLP-1 Agonists
Fuente
Response Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
17/10/2024
Ferias y Congresos
Industria
Salud
Fitness
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Response Pharmaceuticals Announces Enrollment of First Patients in a Phase 2 Study Evaluating RDX-002, a Novel Small Molecule iMTP Inhibitor, in Patients Discontinuing GLP-1 Agonists & Clinical Presentation at Obesity Week
Fuente
Response Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0